Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Texas: - The Don and Sybil Harrington Cancer Center — Amarillo, Texas
- UTMB Health Angleton Danbury Campus — Angleton, Texas
- Houston Methodist San Jacinto Hospital — Baytown, Texas
- MD Anderson in The Woodlands — Conroe, Texas
- Houston Methodist Cypress Hospital — Cypress, Texas
Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Texas: - Texas Tech University Health Sciences Center-Amarillo — Amarillo, Texas
- The Don and Sybil Harrington Cancer Center — Amarillo, Texas
- Dell Children's Medical Center of Central Texas — Austin, Texas
- Saint Joseph Regional Cancer Center — Bryan, Texas
- Driscoll Children's Hospital — Corpus Christi, Texas
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part o…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Texas: - Medical City Dallas Hospital — Dallas, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
- Cook Children's Medical Center — Fort Worth, Texas
Phase 3 Recruiting Industry
This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whos…
Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Texas: - USO-Texas Oncology-Central/South Texas — Austin, Texas
- US Oncology — The Woodlands, Texas
- US Oncology — The Woodlands, Texas
- USO - Texas Oncology Gulf Coast — Webster, Texas
Phase 3 Recruiting Industry
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallo…
Sponsor: AbbVie
NCT ID: NCT05445778
Sites in Texas: - Texas Oncology - Austin Central /ID# 269531 — Austin, Texas
- Texas Oncology - Bedford /ID# 269571 — Bedford, Texas
- Texas Oncology - Methodist Dallas Cancer Center /ID# 269554 — Dallas, Texas
- Texas Oncology - Fort Worth Cancer Center /ID# 269532 — Fort Worth, Texas
- US Oncology Research Investigational Products Center /ID# 278746 — Irving, Texas
Phase 2, Phase 3 Recruiting Industry
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Sites in Texas: - Texas Oncology-Bedford — Bedford, Texas
- Houston Area Locations- Woodlands — Conroe, Texas
- Texas Oncology-Presbyterian Cancer Center Dallas — Dallas, Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- Texas Oncology Paris — Fort Worth, Texas
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Texas: - Texas Oncology Central — Austin, Texas
- Texas Oncology-Fort Worth Cancer Center — Fort Worth, Texas
- Houston Methodist — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology — San Antonio, Texas
Phase 3 Recruiting Industry
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…
Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Texas: - Baylor College of Medicine — Houston, Texas
- University of Texas Science Center at Houston, McGovern Medical School — Houston, Texas
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Texas: - Texas Oncology - Central/South Texas ( Site 8009) — Austin, Texas
- Texas Oncology - DFW ( Site 8001) — Fort Worth, Texas
- Texas Oncology - San Antonio ( Site 8005) — San Antonio, Texas
- Texas Oncology - Gulf Coast ( Site 8003) — Webster, Texas
Phase 3 Recruiting Academic/Other
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Sites in Texas: - Lyndon Baines Johnson General — Houston, Texas
- Houston Methodist — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Academic/Other
The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard intra-operative …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT04878094
Sites in Texas: - Houston Methodist Cancer Center (Data Collection Only) — Houston, Texas
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Texas: - Hendrick Medical Center — Abilene, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Lyndon Baines Johnson General Hospital — Houston, Texas
- Houston Methodist Hospital — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting NIH
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Lyndon Baines Johnson General Hospital — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
Phase 2 Recruiting NIH
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Texas: - Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…
Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Texas: - Texas Oncology - Austin Central /ID# 275046 — Austin, Texas
- Texas Oncology - Fort Worth Cancer Center /ID# 275043 — Fort Worth, Texas
- Houston Methodist Hospital /ID# 274568 — Houston, Texas
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090 — San Antonio, Texas
- Texas Oncology - The Woodlands /ID# 275015 — The Woodlands, Texas
Phase 2 Recruiting Industry
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Texas: - Site 0103 - University of Texas MD Anderson Cancer Center — Houston, Texas
- Site 0234 - University of Texas Health, Memorial Hermann Hospital — Houston, Texas
- Site 0203 - Texas Oncology — Tyler, Texas
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Texas: - Texas Oncology-Austin Center — Austin, Texas
- Houston Methodist Cancer Center — Houston, Texas
- Cancer Care Center of South Texas-Medical Center — San Antonio, Texas
- Texas Oncology-Tyler — Tyler, Texas
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Texas: - USOR Texas Oncology — Abilene, Texas
- Texas Oncology - Central / South Texas — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- USOR Texas Oncology — Fort Worth, Texas
- Texas Oncology - Northeast TX — Tyler, Texas
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas: - New Experimental Therapeutics - NEXT Oncology — Austin, Texas
- UTSW - Moody Outpatient Center - Parkland Health — Dallas, Texas
- UT Southwest Simmons Cancer Center — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Texas: - Mary Crowley Cancer Research Center — Dallas, Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- University of Texas Southwestern — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- START San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Texas: - Research Site 135 — Austin, Texas
- Research Site 120 — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Texas: - Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas: - Mary Crowley Cancer Research — Dallas, Texas
- MD Anderson — Houston, Texas
- NEXT Dallas — Irving, Texas
- NEXT Oncology San Antonio — San Antonio, Texas
- START Texas — San Antonio, Texas
Phase 2 Recruiting Industry
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Sponsor: Faeth Therapeutics
NCT ID: NCT06463028
Sites in Texas: - Texas Oncology - West Texas — El Paso, Texas
- Texas Oncology - Gulf Coast — The Woodlands, Texas